

Helio S Sader

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/967899/publications.pdf>

Version: 2024-02-01

470
papers

19,641
citations

9786

73
h-index

30922

102
g-index

473
all docs

473
docs citations

473
times ranked

10998
citing authors

#	ARTICLE	IF	CITATIONS
1	Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018â€“2020). <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115557.	1.8	21
2	Comparative activity of newer β -lactam/ β -lactamase inhibitor combinations against <i>Pseudomonas aeruginosa</i> from patients hospitalized with pneumonia in European medical centers in 2020. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 319-324.	2.9	12
3	Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010â€“2019). <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0166721.	3.2	6
4	Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019â€“2020). <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 477-487.	2.9	12
5	Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019. <i>International Journal of Infectious Diseases</i> , 2022, 116, 306-312.	3.3	2
6	Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018â€“2020). <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 867-873.	2.9	5
7	Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 103, 115673.	1.8	2
8	<i>In Vitro</i> Potency and Spectrum of the Novel Polymyxin MRX-8 Tested against Clinical Isolates of Gram-Negative Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0013922.	3.2	8
9	Update on the in vitro activity of dalbavancin against indicated species (<i>Staphylococcus aureus</i> ,) Tj ETQq1 1 0.784314 rgBT /Overlook United States hospitals in 2017â€“2019. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 99, 115195.	1.8	9
10	Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> Isolates from United States Medical Centers in 2016â€“2018. <i>Microbial Drug Resistance</i> , 2021, 27, 342-349.	2.0	20
11	Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 659-666.	3.0	36
12	Ceftaroline activity against <i>Staphylococcus aureus</i> isolated from patients with infective endocarditis, worldwide (2010â€“2019). <i>International Journal of Infectious Diseases</i> , 2021, 102, 524-528.	3.3	6
13	Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by species. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 24, 48-52.	2.2	5
14	Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2833-2838.	3.0	13
15	Tedizolid activity against a multicentre worldwide collection of <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> recovered from patients with pneumonia (2017â€“2019). <i>International Journal of Infectious Diseases</i> , 2021, 107, 92-100.	3.3	9
16	Antimicrobial activity of dalbavancin and comparators against <i>Staphylococcus aureus</i> causing pneumonia in patients with and without cystic fibrosis. <i>International Journal of Infectious Diseases</i> , 2021, 107, 69-71.	3.3	1
17	Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against <i>Pseudomonas aeruginosa</i> from cystic fibrosis patients. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab126.	2.1	17
18	Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from respiratory samples of patients hospitalized with pneumonia in Western Europe, Eastern Europe and the USA: results from the SENTRY Antimicrobial Surveillance Program (2016â€“19). <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab117.	2.1	7

#	ARTICLE	IF	CITATIONS
19	Characterization of <i>Enterobacter cloacae</i> and <i>Citrobacter freundii</i> species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agents. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab136.	2.1	3
20	Characterization of a <i>vga</i> gene variant recovered from a <i>Staphylococcus saprophyticus</i> causing a community-acquired urinary tract infection: report from the SENTRY Antimicrobial Surveillance Program 2017. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 100, 115398.	1.8	0
21	Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3125-3134.	3.0	33
22	Ceftolozane-tazobactam activity against clinical isolates of <i>Pseudomonas aeruginosa</i> from ICU patients with pneumonia: United States, 2015–2018. <i>International Journal of Infectious Diseases</i> , 2021, 112, 321-326.	3.3	9
23	Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106439.	2.5	36
24	Anti-staphylococcal lysin, LSVT-1701, activity: In vitro susceptibility of <i>Staphylococcus aureus</i> and coagulase-negative staphylococci (CoNS) clinical isolates from around the world collected from 2002 to 2019. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115471.	1.8	2
25	EVALUATION OF THE IN VITRO ACTIVITY OF CEFTAROLINE AND COMPARATORS AGAINST STREPTOCOCCUS PNEUMONIAE ISOLATES FROM THE UNITED STATES: RESULTS FROM 10 YEARS OF THE AWARE SURVEILLANCE PROGRAM (2011-2020). <i>Chest</i> , 2021, 160, A513.	0.8	1
26	Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against <i>Pseudomonas aeruginosa</i> from patients with skin and soft tissue infections. <i>International Journal of Infectious Diseases</i> , 2021, 113, 279-281.	3.3	15
27	ANTIMICROBIAL ACTIVITY OF DALBAVANCIN AGAINST GRAM-POSITIVE BACTERIA ISOLATED FROM PATIENTS WITH INFECTIVE ENDOCARDITIS FROM THE UNITED STATES AND EUROPE (2016-2020): RESULTS FROM THE INTERNATIONAL DALBAVANCIN EVALUATION OF ACTIVITY (IDEA) PROGRAM. <i>Chest</i> , 2021, 160, A510.	0.8	0
28	Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017–2018). <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114833.	1.8	32
29	Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America. <i>International Journal of Infectious Diseases</i> , 2020, 91, 32-37.	3.3	24
30	Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	23
31	Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012–18. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2907-2913.	3.0	22
32	<i>In Vitro</i> Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	23
33	Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary <i>Stenotrophomonas maltophilia</i> Isolates from Medical Centers Worldwide. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	14
34	ANTIMICROBIAL ACTIVITY OF CEFTAROLINE AGAINST STAPHYLOCOCCUS AUREUS ISOLATED FROM PATIENTS WITH INFECTIVE ENDOCARDITIS WORLDWIDE (2010-2019). <i>Chest</i> , 2020, 158, A333.	0.8	0
35	Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of <i>Haemophilus influenzae</i> from the United States and Europe. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	2
36	Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β -lactamases with ceftazidime hydrolytic activity lead to elevated MIC values. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106011.	2.5	20

#	ARTICLE	IF	CITATIONS
37	Correlation between Broth Microdilution and Disk Diffusion Results when Testing Ceftazidime-Avibactam against a Challenge Collection of <i>Enterobacterales</i> Isolates: Results from a Multilaboratory Study. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	5
38	Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014–2018): therapeutic options for multidrug-resistant bacteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115108.	1.8	15
39	Antimicrobial Activity of Telavancin Tested <i>In Vitro</i> Against a Global Collection of Gram-Positive Pathogens, Including Multidrug-Resistant Isolates (2015–2017). <i>Microbial Drug Resistance</i> , 2020, 26, 934-943.	2.0	8
40	Assessment of Tedizolid <i>In Vitro</i> Activity and Resistance Mechanisms against a Collection of <i>Enterococcus</i> spp. Causing Invasive Infections, Including Isolates Requiring an Optimized Dosing Strategy for Daptomycin from U.S. and European Medical Centers, 2016 to 2018. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	12
41	Impact of EUCAST, CLSI and USCAST ceftaroline breakpoint changes on the susceptibility of methicillin-resistant <i>Staphylococcus aureus</i> isolates collected from US medical centres (2015–2018). <i>Clinical Microbiology and Infection</i> , 2020, 26, 658-659.	6.0	6
42	Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1518-1524.	3.0	6
43	Activity of Plazomicin Tested against <i>Enterobacterales</i> Isolates Collected from U.S. Hospitals in 2016–2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	14
44	<i>In Vitro</i> Activity of Minocycline against U.S. Isolates of <i>Acinetobacter baumannii</i> - <i>Acinetobacter calcoaceticus</i> Species Complex, <i>Stenotrophomonas maltophilia</i> , and <i>Burkholderia cepacia</i> Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	30
45	Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015–2016 and Characterization of Resistance Mechanisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	25
46	<i>In Vitro</i> Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> (2014–2015) in the United States. <i>Microbial Drug Resistance</i> , 2019, 25, 938-943.	2.0	9
47	Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015–2016). <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	43
48	Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in <i>Pseudomonas aeruginosa</i> clinical isolates from US hospitals. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2588-2595.	3.0	34
49	Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015–2017). <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 95, 114850.	1.8	21
50	Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014–2015). <i>Journal of Chemotherapy</i> , 2019, 31, 188-194.	1.5	18
51	Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against <i>Enterobacteriaceae</i> Isolates Producing Extended-Spectrum β -Lactamases from U.S. Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	37
52	The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	307
53	Antimicrobial Resistance Surveillance and New Drug Development. <i>Open Forum Infectious Diseases</i> , 2019, 6, S5-S13.	0.9	10
54	Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among <i>Enterobacteriaceae</i> Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program. <i>Open Forum Infectious Diseases</i> , 2019, 6, S23-S33.	0.9	124

#	ARTICLE	IF	CITATIONS
55	Antimicrobial Susceptibility of <i>Streptococcus pneumoniae</i> from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997–2016). <i>Open Forum Infectious Diseases</i> , 2019, 6, S14-S23.	0.9	56
56	Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997–2016). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1595-1606.	3.0	49
57	Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America. <i>Journal of Global Antimicrobial Resistance</i> , 2019, 17, 103-108.	2.2	10
58	Antimicrobial Susceptibility of <i>Acinetobacter calcoaceticus</i> – <i>Acinetobacter baumannii</i> Complex and <i>Stenotrophomonas maltophilia</i> Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997–2016). <i>Open Forum Infectious Diseases</i> , 2019, 6, S34-S46.	0.9	136
59	Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014–17). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1928-1933.	3.0	12
60	Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iii35-iii41.	3.0	21
61	Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1306-1310.	3.0	21
62	Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016–2017). <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 304-313.	1.8	19
63	In vitro activity of dihydrofolate reductase inhibitors and other antibiotics against Gram-positive pathogens collected globally between 2004 and 2016. <i>Journal of Global Antimicrobial Resistance</i> , 2019, 16, 236-238.	2.2	4
64	In vitro activity of telavancin against <i>Staphylococcus aureus</i> causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012–2016). <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 167-170.	1.8	0
65	Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016). <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	21
66	Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	32
67	Antimicrobial activity of ceftolozane–tazobactam tested against gram-negative contemporary (2015–2017) isolates from hospitalized patients with pneumonia in US medical centers. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 93-102.	1.8	39
68	ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1880-1887.	3.0	56
69	Surveillance of tigecycline activity tested against clinical isolates from a global (North America,) <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i> <i>Antimicrobial Agents</i> , 2018, 51, 848-853.	2.5	32
70	Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011–2016). <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 608-611.	2.5	46
71	Activity of Ceftolozane-Tazobactam against <i>Pseudomonas aeruginosa</i> and <i>Enterobacteriaceae</i> Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	46
72	Antimicrobial Activity of Dalbavancin against <i>Staphylococcus aureus</i> with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18

#	ARTICLE	IF	CITATIONS
73	Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014–2016). <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 916-922.	3.0	2
74	Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 77-84.	1.8	35
75	Antimicrobial Susceptibility of Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 92, 69-74.	1.8	89
76	Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of <i>Pseudomonas aeruginosa</i> from the United States, Europe, and China. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	35
77	Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010–2014. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 199-204.	1.8	20
78	Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	11
79	Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	61
80	Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia) <i>Journal of Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	2.5	31
81	Ceftazidime–Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 549-554.	2.0	14
82	In Vitro Activities of Ceftaroline and Comparators against <i>Streptococcus pneumoniae</i> Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016). <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	15
83	Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010–2016): concomitant analysis of oritavancin in vitro activity. <i>Journal of Chemotherapy</i> , 2018, 30, 280-289.	1.5	28
84	Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America. <i>International Journal of Infectious Diseases</i> , 2018, 77, 82-86.	3.3	22
85	Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	8
86	Multidrug-resistant <i>Pseudomonas aeruginosa</i> from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1499-1510.	2.7	22
87	Antimicrobial Susceptibility of <i>Pseudomonas aeruginosa</i> to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	37
88	Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–2017). <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3053-3059.	3.0	55
89	Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–2016. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2748-2756.	3.0	47
90	Murepavadin activity tested against contemporary (2016–2017) clinical isolates of XDR <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2400-2404.	3.0	50

#	ARTICLE	IF	CITATIONS
91	Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014). <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 87, 261-265.	1.8	6
92	Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	50
93	Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	24
94	<i>Pseudomonas aeruginosa</i> Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	91
95	Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014). <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 177-183.	1.8	30
96	WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	63
97	Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 486-491.	2.0	19
98	Antimicrobial Susceptibility Trends among <i>Staphylococcus aureus</i> Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	29
99	WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β -lactamases. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1696-1703.	3.0	81
100	Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 198-200.	1.8	29
101	Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 184-187.	1.8	13
102	Ceftaroline Activity Against Multidrug-Resistant <i>Streptococcus pneumoniae</i> from U.S. Medical Centers (2014) and Molecular Characterization of a Single Ceftaroline Nonsusceptible Isolate. <i>Microbial Drug Resistance</i> , 2017, 23, 571-579.	2.0	11
103	Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying <i>bla</i> _{KPC} Collected in U.S. Hospitals from 2012 to 2015. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	47
104	Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents. <i>Journal of Global Antimicrobial Resistance</i> , 2017, 8, 28-32.	2.2	8
105	Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015). <i>Brazilian Journal of Infectious Diseases</i> , 2017, 21, 627-637.	0.6	35
106	Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> Isolates from U.S. Medical Centers, 2013 to 2016. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	89
107	In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions. <i>Microbial Drug Resistance</i> , 2017, 23, 718-726.	2.0	10
108	Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015). <i>Journal of Global Antimicrobial Resistance</i> , 2017, 11, 4-7.	2.2	9

#	ARTICLE	IF	CITATIONS
109	Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014). <i>Journal of Global Antimicrobial Resistance</i> , 2017, 10, 271-276.	2.2	16
110	Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β -Lactamase Inhibitor and a Fourth-Generation Cephalosporin. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3130-3134.	3.9	2
111	The application of in vitro surveillance data for antibacterial dose selection. <i>Current Opinion in Pharmacology</i> , 2017, 36, 130-138.	3.5	4
112	Enhanced activity of cefepime-tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 89, 305-309.	1.8	12
113	Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016). <i>Open Forum Infectious Diseases</i> , 2017, 4, S368-S368.	0.9	3
114	Evolution of Ceftaroline-Resistant Mrsa in a Child with Cystic Fibrosis Following Repeated Antibiotic Exposure. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 813-815.	2.0	16
115	Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2558-2563.	3.2	13
116	Surveillance for linezolid resistance via the Zyvox [®] Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1860-1865.	3.0	63
117	In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013). <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 495-499.	2.5	16
118	Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014). <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 144-150.	2.5	52
119	Changes in the Frequencies of β -Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against β -Lactamase-Producing Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4770-4777.	3.2	53
120	Ceftaroline activity tested against viridans group streptococci from US hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 84, 232-235.	1.8	6
121	Results from the Solithromycin International Surveillance Program (2014). <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3662-3668.	3.2	28
122	Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014. <i>Surgical Infections</i> , 2016, 17, 473-478.	1.4	13
123	Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 85, 80-84.	1.8	19
124	Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4355-4360.	3.2	26
125	<i>In Vitro</i> Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4407-4411.	3.2	38
126	Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014). <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 86, 300-302.	1.8	6

#	ARTICLE	IF	CITATIONS
127	Longitudinal (2001–14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010–13) analysis of oritavancin <i>in vitro</i> potency. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3453-3458.	3.0	71
128	Oritavancin <i>in vitro</i> activity against contemporary <i>Staphylococcus aureus</i> isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013–2014). <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 86, 303-306.	1.8	10
129	Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant <i>Staphylococcus aureus</i> from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012–2014). <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 86, 76-79.	1.8	32
130	<i>In Vitro</i> Activity of Ceftazidime-Avibactam against Contemporary <i>Pseudomonas aeruginosa</i> Isolates from U.S. Medical Centers by Census Region, 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2537-2541.	3.2	30
131	Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011–2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin. <i>Journal of Chemotherapy</i> , 2016, 28, 83-88.	1.5	9
132	<i>In vitro</i> antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 670-677.	3.0	150
133	Antimicrobial Activity of Ceftaroline Tested against <i>Staphylococcus aureus</i> from Surgical Skin and Skin Structure Infections in US Medical Centers. <i>Surgical Infections</i> , 2016, 17, 443-447.	1.4	12
134	Oritavancin Activity Tested against Molecularly Characterized <i>Staphylococci</i> and <i>Enterococci</i> Displaying Elevated Linezolid MIC Results. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3817-3820.	3.2	2
135	<i>In vitro</i> activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 235-242.	2.5	30
136	<i>In vivo</i> emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis: Table 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1736-1738.	3.0	18
137	Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011–13): Table 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 276-278.	3.0	20
138	Ceftaroline Activity against Bacterial Pathogens Frequently Isolated in U.S. Medical Centers: Results from Five Years of the AWARE Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2458-2461.	3.2	27
139	Ceftazidime-Avibactam Activity against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Isolated in U.S. Medical Centers in 2012 and 2013. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3656-3659.	3.2	74
140	<i>In Vitro</i> Spectrum of Pexiganan Activity When Tested against Pathogens from Diabetic Foot Infections and with Selected Resistance Mechanisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1751-1754.	3.2	59
141	Analysis of 5-year trends in daptomycin activity tested against <i>Staphylococcus aureus</i> and enterococci from European and US hospitals (2009–2013). <i>Journal of Global Antimicrobial Resistance</i> , 2015, 3, 161-165.	2.2	14
142	Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible <i>Citrobacter</i> spp., <i>Enterobacter</i> spp., <i>Serratia marcescens</i> , and <i>Pseudomonas aeruginosa</i> from United States medical centers (2011–2014). <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 389-394.	1.8	25
143	Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 78-84.	1.8	16
144	Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010–2013). <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 183-186.	1.8	58

#	ARTICLE	IF	CITATIONS
145	Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 53-59.	2.5	75
146	Telavancin <i>In Vitro</i> Activity against a Collection of Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates, Including Resistant Subsets, from the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1811-1814.	3.2	24
147	Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013). <i>Journal of Global Antimicrobial Resistance</i> , 2015, 3, 36-39.	2.2	3
148	Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 81, 275-279.	1.8	42
149	Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 73-77.	1.8	34
150	Arbekacin Activity against Contemporary Clinical Bacteria Isolated from Patients Hospitalized with Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3263-3270.	3.2	26
151	Activity of ceftaroline and comparator agents tested against <i>Staphylococcus aureus</i> from patients with bloodstream infections in US medical centres (2009-2013). <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2053-2056.	3.0	28
152	Ceftazidime-Avibactam Activity Tested against Enterobacteriaceae Isolates from U.S. Hospitals (2011 to 2013). <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3509-3517.	3.2	104
153	Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 379-381.	1.8	33
154	Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2727-2730.	3.9	8
155	Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13). <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 498-504.	3.0	32
156	Baseline Activity of Telavancin against Gram-Positive Clinical Isolates Responsible for Documented Infections in U.S. Hospitals (2011-2012) as Determined by the Revised Susceptibility Testing Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 702-706.	3.2	21
157	Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 80, 233-238.	1.8	44
158	Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1579-1581.	3.0	16
159	Oritavancin Activity against <i>Staphylococcus aureus</i> Causing Invasive Infections in U.S. and European Hospitals: a 5-Year International Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2921-2924.	3.2	30
160	Post- β -Lactamase-Inhibitor Effect of Tazobactam in Combination with Ceftolozane on Extended-Spectrum- β -Lactamase-Producing Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2434-2437.	3.2	8
161	Avibactam reverts the ceftazidime MIC ₉₀ of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. <i>Journal of Chemotherapy</i> , 2014, 26, 333-338.	1.5	45
162	Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel. <i>Journal of Chemotherapy</i> , 2014, 26, 202-210.	1.5	12

#	ARTICLE	IF	CITATIONS
163	Activity of Ceftaroline-Avibactam Tested Against Contemporary Enterobacteriaceae Isolates Carrying β -Lactamases Prevalent in the United States. <i>Microbial Drug Resistance</i> , 2014, 20, 436-440.	2.0	15
164	Decreased Ceftriaxone Susceptibility in Emerging (35B and 6C) and Persisting (19A) <i>Streptococcus pneumoniae</i> Serotypes in the United States, 2011-2012: Ceftaroline Remains Active <i>In Vitro</i> among β -Lactam Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4923-4927.	3.2	19
165	Ceftaroline Activity Tested Against Bacterial Isolates From Pediatric Patients. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 837-842.	2.0	20
166	Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009-2011). <i>Journal of Chemotherapy</i> , 2014, 26, 133-138.	1.5	34
167	Antimicrobial Activity of Ceftaroline Tested against Drug-Resistant Subsets of <i>Streptococcus pneumoniae</i> from U.S. Medical Centers. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2468-2471.	3.2	21
168	Ceftobiprole Activity against over 60,000 Clinical Bacterial Pathogens Isolated in Europe, Turkey, and Israel from 2005 to 2010. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3882-3888.	3.2	62
169	Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens: report from the SENTRY Antimicrobial Surveillance Program (2008-2011). <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 284-286.	2.5	8
170	Activity of ceftobiprole against methicillin-resistant <i>Staphylococcus aureus</i> strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 323-327.	2.5	22
171	Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE program, 2009-2011. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 78, 437-442.	1.8	15
172	Variation in Potency and Spectrum of Tigecycline Activity against Bacterial Strains from U.S. Medical Centers since Its Approval for Clinical Use (2006 to 2012). <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2274-2280.	3.2	41
173	Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011). <i>Brazilian Journal of Infectious Diseases</i> , 2014, 18, 187-195.	0.6	18
174	Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 78, 422-428.	1.8	23
175	Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 78, 443-448.	1.8	184
176	Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012). <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 78, 449-456.	1.8	19
177	In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011). <i>Journal of Global Antimicrobial Resistance</i> , 2014, 2, 183-189.	2.2	6
178	Analysis of <i>Staphylococcus aureus</i> clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2065-2075.	3.0	105
179	Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1684-1692.	3.2	129
180	Antimicrobial activity of ceftolozane/tazobactam tested against <i>Pseudomonas aeruginosa</i> and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2713-2722.	3.0	130

#	ARTICLE	IF	CITATIONS
181	Contemporary Diversity of β -Lactamases among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β -Lactamase Groups. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 833-838.	3.2	170
182	Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 533-539.	2.5	123
183	Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: Summary of 8 years of a Worldwide Surveillance Programme (2005-2012). <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 465-469.	2.5	76
184	Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). <i>Journal of Infection</i> , 2014, 69, 266-277.	3.3	75
185	Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 328-334.	2.5	194
186	Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1589-1598.	3.0	61
187	116. <i>Critical Care Medicine</i> , 2014, 42, A1388.	0.9	0
188	Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010. <i>Brazilian Journal of Infectious Diseases</i> , 2013, 17, 564-572.	0.6	7
189	An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 76, 206-213.	1.8	57
190	Educational antimicrobial susceptibility testing as a critical component of microbiology laboratory proficiency programs: American Proficiency Institute results for 2007-2011. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 75, 357-360.	1.8	9
191	Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 75, 304-307.	1.8	100
192	Surveillance of dalbavancin potency and spectrum in the United States (2012). <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 76, 122-123.	1.8	29
193	Comparative potencies of contemporary generic vancomycin lot: in vitro assay results from nine products and a reference reagent-grade sample. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 76, 237-238.	1.8	3
194	Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 76, 217-221.	1.8	64
195	More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 76, 110-112.	1.8	5
196	Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010). <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 337-342.	2.5	30
197	Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 76, 61-68.	1.8	27
198	Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 75, 86-88.	1.8	15

#	ARTICLE	IF	CITATIONS
199	Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β -lactam markers to predict ceftaroline activity against clinically indicated species. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 75, 89-93.	1.8	10
200	Update on antimicrobial susceptibility trends among <i>Streptococcus pneumoniae</i> in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 75, 107-109.	1.8	80
201	Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011). <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 75, 417-422.	1.8	49
202	Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1077-1081.	3.2	48
203	Antimicrobial Activity of Ceftaroline Tested against Staphylococci with Reduced Susceptibility to Linezolid, Daptomycin, or Vancomycin from U.S. Hospitals, 2008 to 2011. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3178-3181.	3.2	43
204	Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012). <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6305-6310.	3.2	177
205	Antimicrobial Activity of Ceftaroline-Avibactam Tested against Clinical Isolates Collected from U.S. Medical Centers in 2010-2011. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1982-1988.	3.2	37
206	Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 636-639.	3.0	27
207	Potency and Spectrum of Activity of AN3365, a Novel Boron-Containing Protein Synthesis Inhibitor, Tested against Clinical Isolates of Enterobacteriaceae and Nonfermentative Gram-Negative Bacilli. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2849-2857.	3.2	37
208	Daptomycin Activity against Uncommonly Isolated Streptococcal and Other Gram-Positive Species Groups. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6378-6380.	3.2	13
209	Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4489-4495.	3.2	73
210	Evaluation of Vancomycin Susceptibility Testing for Methicillin-Resistant <i>Staphylococcus aureus</i> : Comparison of Etest and Three Automated Testing Methods. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2077-2081.	3.9	73
211	AWARE Ceftaroline Surveillance Program (2008-2010): Trends in Resistance Patterns Among <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , and <i>Moraxella catarrhalis</i> in the United States. <i>Clinical Infectious Diseases</i> , 2012, 55, S187-S193.	5.8	68
212	Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2933-2940.	3.2	71
213	Worldwide Appraisal and Update (2010) of Telavancin Activity Tested against a Collection of Gram-Positive Clinical Pathogens from Five Continents. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3999-4004.	3.2	35
214	Oritavancin Activity against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci with Molecularly Characterized Glycopeptide Resistance Genes Recovered from Bacteremic Patients, 2009-2010. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1639-1642.	3.2	31
215	Oritavancin Microbiologic Features and Activity Results From the Surveillance Program in the United States. <i>Clinical Infectious Diseases</i> , 2012, 54, S203-S213.	5.8	39
216	Disk Diffusion and MIC Quality Control Ranges for BC-3205 and BC-3781, Two Novel Pleuromutilin Antibiotics. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3361-3364.	3.9	13

#	ARTICLE	IF	CITATIONS
217	Activity Analyses of Staphylococcal Isolates From Pediatric, Adult, and Elderly Patients: AWARE Ceftaroline Surveillance Program. <i>Clinical Infectious Diseases</i> , 2012, 55, S181-S186.	5.8	30
218	Ceftaroline Potency Among 9 US Census Regions: Report From the 2010 AWARE Program. <i>Clinical Infectious Diseases</i> , 2012, 55, S194-S205.	5.8	16
219	Antimicrobial Activity of the Investigational Pleuromutilin Compound BC-3781 Tested against Gram-Positive Organisms Commonly Associated with Acute Bacterial Skin and Skin Structure Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1619-1623.	3.2	73
220	In Vitro Activity of Ceftaroline Against Multidrug-Resistant <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> : A Review of Published Studies and the AWARE Surveillance Program (2008-2010). <i>Clinical Infectious Diseases</i> , 2012, 55, S206-S214.	5.8	78
221	ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries. <i>Journal of Chemotherapy</i> , 2012, 24, 328-337.	1.5	18
222	Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1170-1175.	3.0	81
223	Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009). <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 72, 113-117.	1.8	21
224	Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative <i>Staphylococcus</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 73, 212-214.	1.8	22
225	Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 73, 354-360.	1.8	222
226	Resistance trends in gram-negative bacteria: surveillance results from two Mexican hospitals, 2005-2010. <i>BMC Research Notes</i> , 2012, 5, 277.	1.4	24
227	LEADER Surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 74, 54-61.	1.8	45
228	Macrolide and tetracycline resistance among <i>Moraxella catarrhalis</i> isolates from 2009 to 2011. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 74, 198-200.	1.8	15
229	Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 74, 412-414.	1.8	65
230	Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β -Lactamases and Methicillin-Resistant <i>Staphylococcus aureus</i> Carrying Various Staphylococcal Cassette Chromosome <i>mec</i> Types. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4779-4785.	3.2	70
231	Characterization of methicillin-resistant <i>Staphylococcus aureus</i> displaying increased MICs of ceftaroline. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1321-1324.	3.0	97
232	Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 39-45.	2.5	36
233	Susceptibility of <i>Klebsiella</i> spp. to colistin and polymyxin B: results from the SENTRY Antimicrobial Surveillance Program (2006-2009). <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 174-175.	2.5	16
234	Comparative activity of linezolid against respiratory tract infection isolates of <i>Staphylococcus aureus</i> : an 11-year report from the SENTRY Antimicrobial Surveillance Program. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 584-585.	2.5	4

#	ARTICLE	IF	CITATIONS
235	Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, iii69-iii80.	3.0	43
236	Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009). <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 223-227.	1.8	31
237	Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant <i>Staphylococcus aureus</i> and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010). <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 70, 412-416.	1.8	44
238	Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010). <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 93-97.	1.8	22
239	Plasmid-borne vga(A)-encoding gene in methicillin-resistant <i>Staphylococcus aureus</i> ST398 recovered from swine and a swine farmer in the United States. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 177-180.	1.8	18
240	Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2070-2074.	3.0	295
241	Antimicrobial Activity of Daptomycin Tested Against Gram-Positive Strains Collected in European Hospitals: Results from 7 Years of Resistance Surveillance (2003-2009). <i>Journal of Chemotherapy</i> , 2011, 23, 200-206.	1.5	23
242	LEADER Program Results for 2009: an Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3684-3690.	3.2	79
243	Determination of Disk Diffusion and MIC Quality Control Ranges for GSK1322322, a Novel Peptide Deformylase Inhibitor. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3928-3930.	3.9	21
244	Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, <i>Pseudomonas aeruginosa</i> , and <i>Bacteroides fragilis</i> Strains Having Various Resistance Phenotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2390-2394.	3.2	112
245	The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). <i>Journal of Infection</i> , 2010, 61, 476-483.	3.3	33
246	The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). <i>Journal of Infection</i> , 2010, 60, 440-451.	3.3	28
247	Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008). <i>Pathology</i> , 2010, 42, 470-473.	0.6	15
248	Novel Chromosome-Encoded CTX-M-78 β -Lactamase from a <i>Kluyvera georgiana</i> Clinical Isolate as a Putative Origin of CTX-M-25 Subgroup. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3070-3071.	3.2	21
249	Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1383-1383.	3.2	6
250	Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2396-2404.	3.0	35
251	Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, iv17-iv31.	3.0	61
252	Antimicrobial Susceptibilities of a Worldwide Collection of <i>Stenotrophomonas maltophilia</i> Isolates Tested against Tigecycline and Agents Commonly Used for <i>S. maltophilia</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2735-2737.	3.2	93

#	ARTICLE	IF	CITATIONS
253	Antimicrobial Susceptibility Patterns of KPC-Producing or CTX-M-Producing Enterobacteriaceae. <i>Microbial Drug Resistance</i> , 2010, 16, 61-65.	2.0	45
254	Characterization of Baseline Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates Recovered from Phase IV Clinical Trial for Linezolid. <i>Journal of Clinical Microbiology</i> , 2010, 48, 568-574.	3.9	40
255	Activity of Ceftaroline against Recent Emerging Serotypes of <i>Streptococcus pneumoniae</i> in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2716-2719.	3.2	67
256	Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 282-287.	2.5	29
257	Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 537-543.	2.5	43
258	Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 28-32.	2.5	52
259	Evolving trends in <i>Streptococcus pneumoniae</i> resistance: implications for therapy of community-acquired bacterial pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 197-204.	2.5	82
260	Activity of telavancin and comparator antimicrobial agents tested against <i>Staphylococcus</i> spp. isolated from hospitalised patients in Europe (2007-2008). <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 374-379.	2.5	22
261	Antimicrobial activity of daptomycin tested against <i>Staphylococcus aureus</i> with vancomycin MIC of 2 µg/mL isolated in the United States and European hospitals (2006-2008). <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 66, 329-331.	1.8	19
262	Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 67, 359-368.	1.8	31
263	Comprehensive assessment of tigecycline activity tested against a worldwide collection of <i>Acinetobacter</i> spp. (2005-2009). <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 68, 307-311.	1.8	41
264	Declining antimicrobial susceptibility of <i>Streptococcus pneumoniae</i> in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009). <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 68, 334-336.	1.8	54
265	Antimicrobial susceptibility of gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005-2008). <i>Brazilian Journal of Infectious Diseases</i> , 2009, 13, 90-98.	0.6	71
266	In Vitro Activity of Ceftaroline Alone and in Combination against Clinical Isolates of Resistant Gram-Negative Pathogens, Including β-Lactamase-Producing <i>Enterobacteriaceae</i> and <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2360-2366.	3.2	51
267	Dissemination of a bla _{VIM-2} -Carrying Integron Among <i>Enterobacteriaceae</i> Species in Mexico: Report from the SENTRY Antimicrobial Surveillance Program. <i>Microbial Drug Resistance</i> , 2009, 15, 33-35.	2.0	19
268	Daptomycin Activity Tested Against Linezolid-Nonsusceptible Gram-Positive Clinical Isolates. <i>Microbial Drug Resistance</i> , 2009, 15, 245-249.	2.0	14
269	Nine-Hospital Study Comparing Broth Microdilution and Etest Method Results for Vancomycin and Daptomycin against Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3162-3165.	3.2	87
270	Potency and Bactericidal Activity of Iclaprim against Recent Clinical Gram-Positive Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2171-2175.	3.2	56

#	ARTICLE	IF	CITATIONS
271	Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4127-4132.	3.2	113
272	Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among <i>Staphylococcus aureus</i> causing bloodstream infections in nine USA hospitals. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 1024-1028.	3.0	56
273	TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 716-720.	3.0	37
274	Correlation of Cefoxitin MICs with the Presence of <i>mecA</i> in <i>Staphylococcus</i> spp. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1902-1905.	3.9	17
275	Antimicrobial Resistance among Gram-Positive Bacteria Isolated in Latin American Hospitals. <i>Journal of Chemotherapy</i> , 2009, 21, 611-620.	1.5	19
276	Activities of Dalbavancin against a Worldwide Collection of 81,673 Gram-Positive Bacterial Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1260-1263.	3.2	76
277	In vitro activity of iclaprim and comparison agents tested against <i>Neisseria gonorrhoeae</i> including medium growth supplement effects. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 339-341.	1.8	1
278	Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007). <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 440-446.	1.8	14
279	In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 434-439.	1.8	9
280	Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 65, 319-322.	1.8	19
281	Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 65, 158-162.	1.8	90
282	Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007). <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 65, 331-334.	1.8	41
283	Activity of daptomycin against Gram-positive bacterial isolates from Indian medical centres (2006-2007). <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 497-499.	2.5	12
284	Antimicrobial activity of daptomycin and selected comparators tested against bloodstream <i>Staphylococcus aureus</i> isolates from hemodialysis patients. <i>International Journal of Infectious Diseases</i> , 2009, 13, 291-295.	3.3	8
285	Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 415-425.	1.8	22
286	Update on the In Vitro Activity of Daptomycin Tested against 17,193 Gram-positive Bacteria Isolated From European Medical Centers (2005-2007). <i>Journal of Chemotherapy</i> , 2009, 21, 500-506.	1.5	16
287	Antimicrobial activity of tigecycline against community-acquired methicillin-resistant <i>Staphylococcus aureus</i> isolates recovered from North American medical centers. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 60, 433-436.	1.8	41
288	Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 60, 421-427.	1.8	32

#	ARTICLE	IF	CITATIONS
289	In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant <i>Staphylococcus aureus</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 60, 399-403.	1.8	21
290	Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006). <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 61, 235-239.	1.8	42
291	Antimicrobial activity of ceftobiprole, a novel anti- β -lactamase methicillin-resistant <i>Staphylococcus aureus</i> cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 61, 86-95.	1.8	90
292	Interpretive categorical accuracy of fluoroquinolone reference broth microdilution MIC results when testing <i>Streptococcus pneumoniae</i> : selection of a surrogate testing agent. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 62, 460-463.	1.8	4
293	Antimicrobial Activities of Tigecycline and Other Broad-Spectrum Antimicrobials Tested against Serine Carboxypeptidase- and Metallo- β -Lactamase-Producing Enterobacteriaceae : Report from the SENTRY Antimicrobial Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 570-573.	3.2	131
294	Characterization of Vancomycin-Heteroresistant <i>Staphylococcus aureus</i> from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007). <i>Journal of Clinical Microbiology</i> , 2008, 46, 2950-2954.	3.9	132
295	RmtD 16S RNA Methylase in Epidemiologically Unrelated SPM-1-Producing <i>Pseudomonas aeruginosa</i> Isolates from Brazil. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1587-1588.	3.2	19
296	Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1092-1098.	3.0	44
297	Increased Antimicrobial Susceptibility Profiles among Polymyxin-Resistant <i>Acinetobacter baumannii</i> Clinical Isolates. <i>Clinical Infectious Diseases</i> , 2008, 46, 1324-1326.	5.8	20
298	Antimicrobial Activity of DC-159a, a New Fluoroquinolone, against 1,149 Recently Collected Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3763-3775.	3.2	16
299	Antimicrobial Activity of Omiganan Pentahydrochloride against Contemporary Fungal Pathogens Responsible for Catheter-Associated Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1187-1189.	3.2	43
300	IMP-15-Producing <i>Pseudomonas aeruginosa</i> Strain Isolated in a U.S. Medical Center: a Recent Arrival from Mexico. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2289-2290.	3.2	10
301	Antimicrobial Activities of Ceftaroline and ME1036 Tested against Clinical Strains of Community-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1153-1155.	3.2	74
302	Frequency of Occurrence and Daptomycin Susceptibility Rates of Gram-positive Organisms Causing Bloodstream. <i>Journal of Chemotherapy</i> , 2008, 20, 570-576.	1.5	12
303	Activity of daptomycin and selected antimicrobial agents tested against <i>Staphylococcus aureus</i> from patients with bloodstream infections hospitalized in European medical centers. <i>Journal of Chemotherapy</i> , 2008, 20, 28-32.	1.5	5
304	Reevaluation of Clinical and Laboratory Standards Institute Disk Diffusion Breakpoints for Tetracyclines for Testing Enterobacteriaceae. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1640-1643.	3.9	22
305	Characterization of an Integron Carrying bla IMP-1 and a New Aminoglycoside Resistance Gene, aac(6)-31, and Its Dissemination among Genetically Unrelated Clinical Isolates in a Brazilian Hospital. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2611-2614.	3.2	60
306	Detection of Inducible Clindamycin Resistance in Staphylococci by Broth Microdilution Using Erythromycin-Clindamycin Combination Wells. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3954-3957.	3.9	16

#	ARTICLE	IF	CITATIONS
307	Activity of Dalbavancin Tested against <i>Staphylococcus</i> spp. and β -Hemolytic <i>Streptococcus</i> spp. Isolated from 52 Geographically Diverse Medical Centers in the United States. <i>Journal of Clinical Microbiology</i> , 2007, 45, 998-1004.	3.9	33
308	Multicenter Studies of Tigecycline Disk Diffusion Susceptibility Results for <i>Acinetobacter</i> spp. <i>Journal of Clinical Microbiology</i> , 2007, 45, 227-230.	3.9	157
309	Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of <i>Pseudomonas aeruginosa</i> , including multidrug-resistant <i>P. aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 365-370.	3.0	87
310	In71, an <i>Enterobacter cloacae</i> bla _{VIM-1} -Carrying Integron Related to In70.2 from Italian <i>Pseudomonas aeruginosa</i> Isolates: A SENTRY Antimicrobial Surveillance Program Report. <i>Microbial Drug Resistance</i> , 2007, 13, 130-134.	2.0	8
311	Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, 109-116.	1.8	26
312	Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of <i>Escherichia coli</i> and <i>Klebsiella</i> spp. with an ESBL phenotype. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, 341-344.	1.8	44
313	Bactericidal activity of cefepime and ceftriaxone tested against <i>Streptococcus pneumoniae</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, 345-349.	1.8	1
314	Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, 459-465.	1.8	61
315	In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant <i>Enterobacteriaceae</i> strains (1999-2004). <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 58, 27-32.	1.8	8
316	Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 58, 19-26.	1.8	32
317	Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, S5-S12.	1.8	37
318	Garenoxacin activity against isolates from patients hospitalized with community-acquired pneumonia and multidrug-resistant <i>Streptococcus pneumoniae</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 58, 1-7.	1.8	12
319	Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 58, 9-17.	1.8	19
320	Zyvox® Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 59, 199-209.	1.8	41
321	LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 59, 309-317.	1.8	100
322	Selection of a surrogate β -lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 59, 467-472.	1.8	14
323	Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 29-43.	4.4	18
324	Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox® Annual Appraisal of Potency and Spectrum Study. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 295-301.	2.5	29

#	ARTICLE	IF	CITATIONS
325	Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 143-149.	2.5	63
326	Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 514-520.	2.5	11
327	Evaluation of the Susceptibility profiles, genetic similarity and presence of qnr gene in <i>Escherichia coli</i> resistant to ciprofloxacin isolated in Brazilian hospitals. <i>Brazilian Journal of Infectious Diseases</i> , 2007, 11, 40-43.	0.6	21
328	Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). <i>BMC Infectious Diseases</i> , 2007, 7, 29.	2.9	55
329	Occurrence and Characterization of Carbapenemase-Producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program (2000-2004). <i>Microbial Drug Resistance</i> , 2006, 12, 223-230.	2.0	133
330	Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004). <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 54, 249-257.	1.8	20
331	Dissemination of IMP-1 Metallo- β -Lactamase-Producing <i>Acinetobacter</i> Species in a Brazilian Teaching Hospital. <i>Infection Control and Hospital Epidemiology</i> , 2006, 27, 742-747.	1.8	46
332	Emergence of linezolid-resistant <i>Staphylococcus aureus</i> during treatment of pulmonary infection in a patient with cystic fibrosis. <i>International Journal of Antimicrobial Agents</i> , 2006, 27, 300-302.	2.5	110
333	Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. <i>International Journal of Antimicrobial Agents</i> , 2006, 27, 557-560.	2.5	33
334	Occurrence of plasmidic AmpC type β -lactamase-mediated resistance in <i>Escherichia coli</i> : report from the SENTRY Antimicrobial Surveillance Program (North America, 2004). <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 578-581.	2.5	43
335	Emergence and epidemiology of fluoroquinolone-resistant <i>Streptococcus pneumoniae</i> strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004). <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 54, 157-164.	1.8	19
336	Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 54, 149-153.	1.8	55
337	Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 56, 57-62.	1.8	73
338	Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003). <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 55, 157-164.	1.8	15
339	Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 56, 63-68.	1.8	33
340	Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 55, 351-356.	1.8	7
341	Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: Report from the MYSTIC Program (1999-2005). <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 56, 367-372.	1.8	124
342	Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines?. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2006, 101, 741-748.	1.6	70

#	ARTICLE	IF	CITATIONS
343	Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). <i>Clinical Microbiology and Infection</i> , 2006, 12, 844-852.	6.0	110
344	Activity of Retapamulin (SB-275833), a Novel Pleuromutilin, against Selected Resistant Gram-Positive Cocci. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2583-2586.	3.2	112
345	The Activity of Daptomycin Against Wild-Type <i>Staphylococcus aureus</i> and Strains with Reduced Susceptibility to Vancomycin. <i>Clinical Infectious Diseases</i> , 2006, 43, 798-799.	5.8	35
346	Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 279-287.	3.0	71
347	Accuracy of Three Automated Systems (MicroScan WalkAway, VITEK, and VITEK 2) for Susceptibility Testing of <i>Pseudomonas aeruginosa</i> against Five Broad-Spectrum Beta-Lactam Agents. <i>Journal of Clinical Microbiology</i> , 2006, 44, 1101-1104.	3.9	58
348	Carbapenem Susceptibility Discords among <i>Acinetobacter</i> Isolates. <i>Clinical Infectious Diseases</i> , 2006, 42, 158-158.	5.8	22
349	Daptomycin Bactericidal Activity and Correlation between Disk and Broth Microdilution Method Results in Testing of <i>Staphylococcus aureus</i> Strains with Decreased Susceptibility to Vancomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2330-2336.	3.2	77
350	Development of decreased susceptibility to daptomycin and vancomycin in a <i>Staphylococcus aureus</i> strain during prolonged therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 481-483.	3.0	56
351	Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 914-923.	3.0	25
352	Selection of a Surrogate Agent (Vancomycin or Teicoplanin) for Initial Susceptibility Testing of Dalbavancin: Results from an International Antimicrobial Surveillance Program. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2622-2625.	3.9	18
353	Changing Antimicrobial Susceptibility Patterns among <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> from Brazil: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004). <i>Microbial Drug Resistance</i> , 2006, 12, 91-98.	2.0	9
354	Comment on: Linezolid resistance in coagulase-negative staphylococci. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 899-900.	3.0	4
355	Contemporary Prevalence of BRO β -Lactamases in <i>Moraxella catarrhalis</i> : Report from the SENTRY Antimicrobial Surveillance Program (North America, 1997 to 2004). <i>Journal of Clinical Microbiology</i> , 2006, 44, 3775-3777.	3.9	21
356	IMPs, VIMs and SPMs: the diversity of metallo- β -lactamases produced by carbapenem-resistant <i>Pseudomonas aeruginosa</i> in a Brazilian hospital. <i>Clinical Microbiology and Infection</i> , 2005, 11, 73-76.	6.0	80
357	In vitro activity of tigecycline, a new glycycline, tested against 1,326 clinical bacterial strains isolated from Latin America. <i>Brazilian Journal of Infectious Diseases</i> , 2005, 9, 348-356.	0.6	25
358	Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002). <i>Memorias Do Instituto Oswaldo Cruz</i> , 2005, 100, 571-577.	1.6	37
359	Emerging Metallo- β -Lactamase-Mediated Resistances: A Summary Report from the Worldwide SENTRY Antimicrobial Surveillance Program. <i>Clinical Infectious Diseases</i> , 2005, 41, S276-S278.	5.8	72
360	Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3501-3512.	3.2	137

#	ARTICLE	IF	CITATIONS
361	Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 1047-1052.	3.0	33
362	Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical Importance. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1468-1476.	3.2	52
363	Daptomycin <i>In Vitro</i> Activity Tested Against Gram-Positive Strains Collected from European and Latin American Medical Centers in 2003. <i>Journal of Chemotherapy</i> , 2005, 17, 477-483.	1.5	18
364	<i>In Vitro</i> Activity of β -Lactam Antimicrobial Agents in Combination with Aztreonam Tested Against Metallo- β -Lactamase-Producing <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> . <i>Journal of Chemotherapy</i> , 2005, 17, 622-627.	1.5	18
365	Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic <i>Neisseria</i> spp. (<i>Neisseria</i> Tj ETQq1 1 0.784314 rgBT /Over 139-141.	1.8	12
366	Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panels. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 51, 219-221.	1.8	0
367	Reevaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum β -lactamase-producing organisms. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 95-99.	1.8	3
368	Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β -lactamase resistance mechanisms. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 71-74.	1.8	117
369	Therapeutic options among broad-spectrum β -lactams for infections caused by levofloxacin-nonsusceptible <i>Streptococcus pneumoniae</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 129-133.	1.8	12
370	Trends in linezolid susceptibility patterns in 2002: Report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 53-58.	1.8	43
371	Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: Results from the SENTRY Antimicrobial Surveillance Program (1998-2003). <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 265-273.	1.8	55
372	Susceptibility testing accuracy of a CTX-M-type extended-spectrum β -lactamase organism-producing population of Enterobacteriaceae: intermethod analysis for 9 β -lactams. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 53, 131-141.	1.8	2
373	Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 53, 307-310.	1.8	69
374	Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against β -lactamase-producing strains of <i>Haemophilus influenzae</i> and <i>Moraxella catarrhalis</i> ?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 53, 225-231.	1.8	3
375	Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 203-208.	1.8	94
376	Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 195-201.	1.8	55
377	Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 187-193.	1.8	78
378	Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 181-186.	1.8	106

#	ARTICLE	IF	CITATIONS
379	Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 209-213.	1.8	63
380	Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003). <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 53, 329-332.	1.8	26
381	Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 89-92.	2.5	10
382	Dissemination and diversity of metallo- β -lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 57-61.	2.5	93
383	Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 95-109.	2.5	155
384	Susceptibility patterns of <i>Streptococcus pneumoniae</i> isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 282-289.	2.5	24
385	Reproducibility of daptomycin MIC results using dry-form commercial trays with appropriate supplemental calcium content. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 274-275.	2.5	3
386	Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter</i> spp.. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 380-384.	2.5	34
387	Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. <i>International Journal of Antimicrobial Agents</i> , 2005, 26, 13-21.	2.5	55
388	SENTRY antimicrobial surveillance program report: latin american and brazilian results for 1997 through 2001. <i>Brazilian Journal of Infectious Diseases</i> , 2004, 8, 25-79.	0.6	101
389	Genotypic Characterization of Carbapenem-Nonsusceptible <i>Acinetobacter</i> spp. Isolated in Latin America. <i>Microbial Drug Resistance</i> , 2004, 10, 286-291.	2.0	11
390	Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 669-674.	3.0	130
391	Initial results from a longitudinal international surveillance programme for anidulafungin (2003). <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 1051-1056.	3.0	50
392	In Vitro Activities of the Novel Cephalosporin LB 11058 against Multidrug-Resistant Staphylococci and Streptococci. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 53-62.	3.2	81
393	Omiganan Pentahydrochloride (MBI 226), a Topical 12-Amino-Acid Cationic Peptide: Spectrum of Antimicrobial Activity and Measurements of Bactericidal Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3112-3118.	3.2	115
394	Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 290-296.	3.0	95
395	Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 804-807.	3.0	24
396	Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 144-154.	3.0	110

#	ARTICLE	IF	CITATIONS
397	Antimicrobial Susceptibility and Epidemiology of a Worldwide Collection of <i>Chryseobacterium</i> spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001). <i>Journal of Clinical Microbiology</i> , 2004, 42, 445-448.	3.9	230
398	Integron Carrying a Novel Metallo- β -Lactamase Gene, bla IMP-16 , and a Fused Form of Aminoglycoside-Resistant Gene aac(6â€²)-30/aac(6â€²)-Ibâ€² : Report from the SENTRY Antimicrobial Surveillance 3.2 Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4693-4702.		86
399	Evaluation of the prevalence and risk factors for colonization by vancomycin-resistant <i>Enterococcus</i> among patients on dialysis. <i>American Journal of Kidney Diseases</i> , 2004, 44, 337-343.	1.9	37
400	Surveillance in Taiwan Using Molecular Epidemiology for Extended-Spectrum Beta-Lactamase-Producing <i>Klebsiella pneumoniae</i> . <i>Infection Control and Hospital Epidemiology</i> , 2004, 25, 812-818.	1.8	10
401	Evaluation of Three Molecular Typing Techniques for Nonfermentative Gram-Negative Bacilli. <i>Infection Control and Hospital Epidemiology</i> , 2004, 25, 847-851.	1.8	64
402	Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 52-59.	2.5	34
403	Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 111-118.	2.5	162
404	Resistance trends of <i>Acinetobacter</i> spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program. <i>International Journal of Infectious Diseases</i> , 2004, 8, 284-291.	3.3	66
405	Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 48, 137-143.	1.8	136
406	Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of year five (2003). <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 49, 273-281.	1.8	25
407	Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against <i>Streptococcus pneumoniae</i> (1999â€“2002). <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 49, 147-149.	1.8	14
408	Determination of epidemic clonality among multidrug-resistant strains of <i>Acinetobacter</i> spp. and <i>Pseudomonas aeruginosa</i> in the MYSTIC Programme (USA, 1999â€“2003). <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 49, 211-216.	1.8	32
409	Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 50, 73-75.	1.8	44
410	Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: A sample of North American isolates. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 49, 283-287.	1.8	11
411	Antimicrobial activity of daptomycin against multidrug-resistant gram-positive strains collected worldwide. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 50, 201-204.	1.8	65
412	A Pseudo-Outbreak of Vancomycin-Resistant <i>Enterococcus faecium</i> . <i>Infection Control and Hospital Epidemiology</i> , 2003, 24, 461-464.	1.8	4
413	Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18â€³569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997â€“2001). <i>International Journal of Antimicrobial Agents</i> , 2003, 22, 551-556.	2.5	100
414	Emergence of an IMP-like metallo-enzyme in an <i>Acinetobacter baumannii</i> clinical strain from a Brazilian teaching hospital. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 45, 77-79.	1.8	62

#	ARTICLE	IF	CITATIONS
415	Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 45, 149-152.	1.8	42
416	Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001). <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 47, 361-364.	1.8	49
417	Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 47, 377-383.	1.8	8
418	Comparative activity and spectrum of broad-spectrum β -lactams (cefepime, ceftazidime, ceftriaxone,) Tj ETQq0 0 0 rgBT /Overlock 10 T antimicrobial surveillance program (North America: 2001-2002). <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 47, 435-440.	1.8	40
419	Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and β -lactams tested against gram-negative bacilli. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 47, 547-550.	1.8	33
420	Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002). <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 47, 515-525.	1.8	24
421	Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant <i>Pseudomonas aeruginosa</i> producing SPM metallo- β -lactamase. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 699-702.	3.0	195
422	Increasing prevalence of antimicrobial resistance among <i>Pseudomonas aeruginosa</i> isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 140-141.	3.0	89
423	Typing and Molecular Characterization of <i>Streptococcus pneumoniae</i> with Reduced Susceptibility to Cefotaxime Isolated in Latin America. <i>Microbial Drug Resistance</i> , 2003, 9, 345-351.	2.0	6
424	AvaliaÃ§Ã£o da qualidade dos discos com antimicrobianos para testes de disco-difusÃ£o disponÃveis comercialmente no Brasil. <i>Jornal Brasileiro De Patologia E Medicina Laboratorial</i> , 2003, 39, 27.	0.3	9
425	Polymyxin-Resistant <i>Acinetobacter</i> spp. Isolates: What Is Next?. <i>Emerging Infectious Diseases</i> , 2003, 9, 1023-1024.	4.3	54
426	Ability of Latin America laboratories to detect antimicrobial resistance patterns: experience of the SENTRY antimicrobial surveillance program (1997-2000). <i>Brazilian Journal of Infectious Diseases</i> , 2003, 7, 282-9.	0.6	7
427	The use of molecular typing to evaluate the dissemination of antimicrobial resistance among gram-negative rods in Brazilian hospitals. <i>Brazilian Journal of Infectious Diseases</i> , 2003, 7, 360-369.	0.6	11
428	Acute Community-Acquired Pneumonia in Adults: Guidelines for Initial Antimicrobial Therapy Based on Local Evidence from a South American Working Group (ConsenSur). <i>Journal of Chemotherapy</i> , 2002, 14, 635-636.	1.5	9
429	Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. <i>Diagnostic Microbiology and Infectious Disease</i> , 2002, 44, 281-288.	1.8	64
430	Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. <i>Diagnostic Microbiology and Infectious Disease</i> , 2002, 44, 273-280.	1.8	82
431	Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000). <i>Diagnostic Microbiology and Infectious Disease</i> , 2002, 44, 289-299.	1.8	92
432	Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). <i>Diagnostic Microbiology and Infectious Disease</i> , 2002, 44, 301-311.	1.8	62

#	ARTICLE	IF	CITATIONS
433	Salmonella spp. isolates causing bloodstream infections in Latin America: report of antimicrobial activity from the SENTRY Antimicrobial Surveillance Program (1997-2000). <i>Diagnostic Microbiology and Infectious Disease</i> , 2002, 44, 313-318.	1.8	22
434	Molecular Typing and Antimicrobial Susceptibility of Vancomycin-Resistant <i>Enterococcus faecium</i> in Brazil. <i>Infection Control and Hospital Epidemiology</i> , 2002, 23, 19-22.	1.8	20
435	Comparação das atividades antimicrobianas de meropenem e imipenem/cilastatina: o laboratório necessita testar rotineiramente os dois antimicrobianos?. <i>Jornal Brasileiro De Patologia E Medicina Laboratorial</i> , 2002, 38, 13-20.	0.3	4
436	Antimicrobial therapy for community-acquired pneumonia in adults. <i>Brazilian Journal of Infectious Diseases</i> , 2002, 6, 82-87.	0.6	3
437	Emerging Strategies in Infectious Diseases. <i>Drugs</i> , 2001, 61, 553-564.	10.9	41
438	In vitro antimicrobial activity of the aminoglycoside arbekacin tested against oxacillin-resistant <i>Staphylococcus aureus</i> isolated in Brazilian hospitals. <i>Brazilian Journal of Infectious Diseases</i> , 2001, 5, 130-5.	0.6	9
439	Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY antimicrobial surveillance program. <i>Brazilian Journal of Infectious Diseases</i> , 2001, 5, 200-14.	0.6	97
440	In vitro antimicrobial activity of linezolid tested against vancomycin-resistant enterococci isolated in Brazilian hospitals. <i>Brazilian Journal of Infectious Diseases</i> , 2001, 5, 243-51.	0.6	17
441	Antimicrobial resistance in respiratory pathogens isolated in Brazil during 1999-2000. <i>Brazilian Journal of Infectious Diseases</i> , 2001, 5, 294-304.	0.6	8
442	Antimicrobial activity of linezolid against Gram-positive cocci isolated in Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2001, 5, 171-176.	0.6	5
443	Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the Global SMART (GSMART) surveillance study. <i>Brazilian Journal of Infectious Diseases</i> , 2001, 5, 21-31.	0.6	17
444	Activities of BMS 284756 (T-3811) against <i>Haemophilus influenzae</i> , <i>Moraxella catarrhalis</i> , and <i>Streptococcus pneumoniae</i> Isolates from SENTRY Antimicrobial Surveillance Program Medical Centers in Latin America (1999). <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1463-1466.	3.2	22
445	Sensibilidade a antimicrobianos de bactérias isoladas do trato respiratório de pacientes com infecções respiratórias adquiridas na comunidade: resultados brasileiros do Programa SENTRY de Vigilância de Resistência a Antimicrobianos dos anos de 1997 e 1998. <i>Jornal De Pneumologia</i> , 2001, 27, 25-34.	0.1	5
446	Perfil de sensibilidade a antimicrobianos de bactérias isoladas do trato respiratório baixo de pacientes com pneumonia internados em hospitais brasileiros: resultados do Programa SENTRY, 1997 e 1998. <i>Jornal De Pneumologia</i> , 2001, 27, 59-67.	0.1	9
447	<i>Enterococcus faecalis</i> resistant to vancomycin and teicoplanin (VanA phenotype) isolated from a bone marrow transplanted patient in Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2001, 5, 40-46.	0.6	15
448	Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998). <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 45, 295-303.	3.0	134
449	Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from Latin American patients with a diagnosis of pneumonia: results from the SENTRY antimicrobial surveillance program (1998). <i>Diagnostic Microbiology and Infectious Disease</i> , 2000, 37, 63-74.	1.8	18
450	Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: Results from the SENTRY antimicrobial surveillance program, 1997-98. <i>International Journal of Infectious Diseases</i> , 2000, 4, 75-84.	3.3	47

#	ARTICLE	IF	CITATIONS
451	Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: results from the SENTRY Antimicrobial Surveillance Program (1997). <i>Clinical Microbiology and Infection</i> , 1999, 5, 478-487.	6.0	20
452	Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides. <i>Diagnostic Microbiology and Infectious Disease</i> , 1999, 34, 185-191.	1.8	59
453	Nosocomial Infections Caused by Multiresistant <i>Pseudomonas aeruginosa</i> . <i>Infection Control and Hospital Epidemiology</i> , 1999, 20, 620-623.	1.8	59
454	Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). <i>Diagnostic Microbiology and Infectious Disease</i> , 1998, 32, 289-301.	1.8	103
455	Evaluation of the in vitro activity of cefepime compared to other broad-spectrum cephalosporins against clinical isolates from eighteen Brazilian hospitals by using the Etest. <i>Diagnostic Microbiology and Infectious Disease</i> , 1997, 28, 87-92.	1.8	20
456	Use of Macrorestriction Analysis to Demonstrate Interhospital Spread of Multiresistant <i>Acinetobacter baumannii</i> in Sao Paulo, Brazil. <i>Clinical Infectious Diseases</i> , 1996, 23, 631-634.	5.8	41
457	An Outbreak of Multiresistant <i>Acinetobacter baumannii</i> in a University Hospital in São Paulo, Brazil. <i>Infection Control and Hospital Epidemiology</i> , 1996, 17, 366-368.	1.8	44
458	Emerging multiply resistant enterococci among clinical isolates I. Prevalence data from 97 medical center surveillance study in the United States. <i>Diagnostic Microbiology and Infectious Disease</i> , 1995, 21, 85-93.	1.8	152
459	Antimicrobial activity of 11 newer and investigational drugs tested against aerobic isolates from spontaneous bacterial peritonitis. <i>Diagnostic Microbiology and Infectious Disease</i> , 1995, 21, 105-110.	1.8	2
460	Pulsed-field gel electrophoresis of restriction-digested genomic DNA and antimicrobial susceptibility of <i>Xanthomonas maltophilia</i> strains from Brazil, Switzerland and the USA. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 33, 615-618.	3.0	21
461	Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the united states II. Study of the intra- and interlaboratory dissemination of extended-spectrum β -lactamase-producing Enterobacteriaceae. <i>Diagnostic Microbiology and Infectious Disease</i> , 1994, 20, 203-208.	1.8	47
462	Update of lomefloxacin in vitro activity and spectrum. <i>Diagnostic Microbiology and Infectious Disease</i> , 1994, 20, 93-98.	1.8	3
463	Evaluation of Interhospital Spread of Methicillin-Resistant <i>Staphylococcus aureus</i> in Sao Paulo, Brazil, Using Pulsed-Field Gel Electrophoresis of Chromosomal DNA. <i>Infection Control and Hospital Epidemiology</i> , 1994, 15, 320-323.	1.8	16
464	Nosocomial Transmission of <i>Serratia odorifera</i> Biogroup 2: Case Report Demonstration by Macrorestriction Analysis of Chromosomal DNA Using Pulsed-Field Gel Electrophoresis. <i>Infection Control and Hospital Epidemiology</i> , 1994, 15, 390-393.	1.8	7
465	In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers. <i>Diagnostic Microbiology and Infectious Disease</i> , 1993, 17, 143-150.	1.8	18
466	Epidemiologic typing of multiply drug-resistant <i>Pseudomonas aeruginosa</i> isolated from an outbreak in an intensive care unit. <i>Diagnostic Microbiology and Infectious Disease</i> , 1993, 17, 13-18.	1.8	188
467	The fourth-generation cephalosporins: Antimicrobial activity and spectrum definitions using ceftiprome as an example. <i>Antimicrobial Newsletter</i> , 1993, 9, 9-16.	0.9	12
468	Oxacillin- and Quinolone-Resistant <i>Staphylococcus aureus</i> in Sao Paulo, Brazil: A Multicenter Molecular Epidemiology Study. <i>Infection Control and Hospital Epidemiology</i> , 1993, 14, 260-264.	1.8	13

#	ARTICLE	IF	CITATIONS
469	Historical overview of the cephalosporin spectrum: Four generations of structural evolution. Antimicrobial Newsletter, 1992, 8, 75-82.	0.9	22
470	Cefotaxime is extensively used for surgical prophylaxis. American Journal of Surgery, 1992, 164, 28S-38S.	1.8	6